Akebia Therapeutics, Inc. (AKBA): Free Cash Flow
$67.70M
Year ended 2025-12-31
$40.26M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.70M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$40.69M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$23.38M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$73.27M | n/m | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | -$253.02M | n/m | 2023-08-28, From 2021-01-01 |
| 2020-12-31 | -$110.70M | n/m | 2023-08-28, From 2020-01-01 |
| 2019-12-31 | -$264.10M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$99.10M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$57.78M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $55.24M | n/m | 2019-03-26, From 2016-01-01 |
| 2015-12-31 | -$52.82M | n/m | 2018-03-12, From 2015-01-01 |
| 2014-12-31 | -$27.71M | n/m | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | -$11.35M | n/a | 2016-03-14, From 2013-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $67.70M | n/m |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $19.61M | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $105.95M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $41.73M | +7.4% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | -$484.00M | n/m |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | -$73.47M | n/m |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $12.46M | n/m |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$110.44M | n/m |
| Arvinas, Inc. (ARVN) | 2025-12-31 | -$275.70M | n/m |
Compare AKBA, ANAB, KROS, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗